BRAF NP_004324.2:p.V600E

Quiénes somos

  • 5 de abril de 2022
    Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer